Literature DB >> 10738847

Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

D Jaspersen1.   

Abstract

Drug-induced injury of the oesophagus is a common cause of oesophageal complaints. 'Pill-induced' oesophagitis is associated with the ingestion of certain drugs and accounts for many cases of erosive oesophagitis. To date, more than 70 drugs have been reported to induce oesophageal disorders. Antibacterials such as doxycycline, tetracycline and clindamycin are the offending agents in more than 50% of cases. Other commonly prescribed drugs that cause oesophageal injury include aspirin (acetylsalicylic acid), potassium chloride, ferrous sulfate, quinidine, alprenolol and various steroidal and nonsteroidal anti-inflammatory agents. However, many physicians and even more patients are not aware of this problem. Capsules or tablets are commonly delayed in their passage through the oesophagus. Highly caustic coatings, direct medication injury and poor oesophageal clearance of pills can lead to acute inflammation. Oesophageal damage occurs when the caustic contents of a drug remain in the oesophagus long enough to produce mucosal lesions. Taking medications at bedtime or without fluids is a common cause of oesophagitis. The possibility of drug-related damage should be suspected in all cases of oesophagitis, chest pain and dysphagia. History and gastrointestinal endoscopy will confirm the diagnosis. Treatment is supportive, although acid reduction is used frequently as an adjunct. This review reflects the current state of knowledge in this field.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738847     DOI: 10.2165/00002018-200022030-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  91 in total

1.  Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement.

Authors:  W F Lubbe; E S Cadogan; A H Kannemeyer
Journal:  N Z Med J       Date:  1979-11-14

Review 2.  Pill-induced esophageal strictures: clinical features and risk factors for development.

Authors:  G S McCord; R E Clouse
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

3.  Tetracycline-induced esophageal ulcerations.

Authors:  A E Stillman; R J Martin
Journal:  Arch Dermatol       Date:  1979-08

4.  Oesophageal obstruction and ulceration caused by oral potassium therapy.

Authors:  J Pemberton
Journal:  Br Heart J       Date:  1970-03

5.  Candida esophagitis: accuracy of radiographic diagnosis.

Authors:  M S Levine; A J Macones; I Laufer
Journal:  Radiology       Date:  1985-03       Impact factor: 11.105

6.  Multiple ulcerative esophagitis caused by alendronate.

Authors:  G Maconi; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

7.  Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride.

Authors:  J G Henry; J J Shinner; J H Martino; L E Cimino
Journal:  Pediatr Cardiol       Date:  1983 Jul-Sep       Impact factor: 1.655

8.  Drug-induced esophageal strictures.

Authors:  L Bonavina; T R DeMeester; L McChesney; W Schwizer; M Albertucci; R T Bailey
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

Review 9.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Esophageal ulcers associated with tetracycline therapy.

Authors:  T D Crowson; L H Head; W A Ferrante
Journal:  JAMA       Date:  1976-06-21       Impact factor: 56.272

View more
  23 in total

1.  Esophageal ulceration complicating doxycycline therapy.

Authors:  Mohammad A Al-Mofarreh; Ibrahim A Al Mofleh
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Pill-induced esophagitis.

Authors:  J Walter Kikendall
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

3.  Clinical and endoscopic characteristics of drug-induced esophagitis.

Authors:  Su Hwan Kim; Ji Bong Jeong; Ji Won Kim; Seong-Joon Koh; Byeong Gwan Kim; Kook Lae Lee; Mee Soo Chang; Jong Pil Im; Hyoun Woo Kang; Cheol Min Shin
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  [Oral bioavailability of oncological preparations: the intake conditions are often decisive].

Authors:  W Weitschies
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

Review 5.  [Medication-induced dysphagia : A review].

Authors:  C Schwemmle; M Jungheim; S Miller; D Kühn; M Ptok
Journal:  HNO       Date:  2015-07       Impact factor: 1.284

6.  Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.

Authors:  J D Carter; L R Espinoza; R D Inman; K B Sneed; L R Ricca; F B Vasey; J Valeriano; J A Stanich; C Oszust; H C Gerard; A P Hudson
Journal:  Arthritis Rheum       Date:  2010-05

7.  Pill Esophagitis.

Authors:  Nathaniel S. Winstead; Robert Bulat
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

8.  Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance.

Authors:  Tim Frenzel; Chanhung Z Lee; Helen Kim; Nancy J Quinnine; Tomoki Hashimoto; Michael T Lawton; B Joseph Guglielmo; Charles E McCulloch; William L Young
Journal:  Cerebrovasc Dis       Date:  2008-01-23       Impact factor: 2.762

9.  A case of oesophageal ulcer developed after taking homeopathic pill in a young woman.

Authors:  Vito D Corleto; Lidia D'Alonzo; Ermira Zykaj; Antonella Carnuccio; Francesca Chiesara; Cristiano Pagnini; Salvatore Di Somma; Gianfranco Delle Fave
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  Drug-induced esophageal injury with an occult vascular ring.

Authors:  Orlee R Guttman; Mary Zachos
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.